Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $24.3 million.

  • Mirum Pharmaceuticals' Change in Accured Expenses rose 9091.91% to $24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.0 million, marking a year-over-year increase of 2873.04%. This contributed to the annual value of $40.3 million for FY2024, which is 3097.67% up from last year.
  • Mirum Pharmaceuticals' Change in Accured Expenses amounted to $24.3 million in Q3 2025, which was up 9091.91% from $10.6 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Change in Accured Expenses registered a high of $24.3 million during Q3 2025, and its lowest value of -$8.1 million during Q1 2022.
  • Its 5-year average for Change in Accured Expenses is $7.8 million, with a median of $9.2 million in 2023.
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Change in Accured Expenses tumbled by 34491.69% in 2021, and later soared by 25066000.0% in 2023.
  • Quarter analysis of 5 years shows Mirum Pharmaceuticals' Change in Accured Expenses stood at $9.0 million in 2021, then crashed by 100.06% to -$5000.0 in 2022, then skyrocketed by 250660.0% to $12.5 million in 2023, then fell by 25.45% to $9.3 million in 2024, then surged by 160.69% to $24.3 million in 2025.
  • Its Change in Accured Expenses stands at $24.3 million for Q3 2025, versus $10.6 million for Q2 2025 and $11.7 million for Q1 2025.